Início
Explorar
nav.journalClub
Tendências
Mais
synapse
⌘+K
Idioma
Português
Belumosudil Combination Therapy with Extracorporeal Photopheresis in Chronic Graft Versus Host Disease: Results from the Rockstar Study | Synapse
March 3, 2026
Belumosudil Combination Therapy with Extracorporeal Photopheresis in Chronic Graft Versus Host Disease: Results from the Rockstar Study
AS
Amandeep Salhotra
LR
Lauren Rota
Morristown Medical Center
KM
Kathy Marshall
Morristown Medical Center
See all
Key Points
Improved outcomes are observed in chronic graft versus host disease with combination therapy.
Significant positive response rates indicate benefits when using belumosudil alongside extracorporeal photopheresis.
Observational analysis assesses the impact of belumosudil and photopheresis on immune response variations.
This combination therapy may enhance treatment options for patients suffering from chronic graft versus host disease.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Salhotra et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760dec6e9836116a2e054
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.391